EC
RARE icon

EntryPoint Capital’s Ultragenyx Pharmaceutical RARE Stock Holding History

EntryPoint Capital’s Portfolio RARE Stock Details RARE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$547K Buy
+26,119
New +$588K 0.16% 215
2025
Q4 		– Sell
-11,466
Closed -$345K – 824
2025
Q3 		$345K Buy
11,466
+891
+8% +$26.7K 0.13% 308
2025
Q2 		$385K Sell
10,575
-407
-4% -$14.7K 0.19% 181
2025
Q1 		$398K Buy
10,982
+4,043
+58% +$168K 0.18% 189
2024
Q4 		$292K Buy
+6,939
New +$344K 0.12% 383
2024
Q3 		– Sell
-2,531
Closed -$104K – 1037
2024
Q2 		$104K Buy
2,531
+2,257
+824% +$96.4K 0.15% 301
2024
Q1 		$12.8K Buy
+274
New +$12.9K 0.01% 1187

Other funds holding RARE

BlackRock
BlackRock New York $5.7T AUM 30.48% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2B AUM 117.41% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return